464 related articles for article (PubMed ID: 30458168)
1. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
Jain M; Joharapurkar A; Patel V; Kshirsagar S; Sutariya B; Patel M; Patel H; Patel PR
Eur J Pharmacol; 2019 Jan; 843():113-120. PubMed ID: 30458168
[TBL] [Abstract][Full Text] [Related]
2. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia.
Patel VJ; Joharapurkar A; Kshirsagar SG; Patel MS; Savsani HH; Dodiya HS; Rakhasiya MH; Kajavadara C; Valani D; Jain MR
Toxicol Appl Pharmacol; 2024 Feb; 483():116832. PubMed ID: 38266872
[TBL] [Abstract][Full Text] [Related]
3. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats.
Barrett TD; Palomino HL; Brondstetter TI; Kanelakis KC; Wu X; Yan W; Merton KP; Schoetens F; Ma JY; Skaptason J; Gao J; Tran DT; Venkatesan H; Rosen MD; Shankley NP; Rabinowitz MH
Br J Pharmacol; 2015 Aug; 172(16):4078-88. PubMed ID: 25988595
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Jain MR; Joharapurkar AA; Pandya V; Patel V; Joshi J; Kshirsagar S; Patel K; Patel PR; Desai RC
Drug Res (Stuttg); 2016 Feb; 66(2):107-12. PubMed ID: 26367279
[TBL] [Abstract][Full Text] [Related]
5. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats.
Theurl M; Nairz M; Schroll A; Sonnweber T; Asshoff M; Haschka D; Seifert M; Willenbacher W; Wilflingseder D; Posch W; Murphy AT; Witcher DR; Theurl I; Weiss G
Haematologica; 2014 Sep; 99(9):1516-24. PubMed ID: 24895335
[TBL] [Abstract][Full Text] [Related]
7. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Kajavadara C; Valani D; Jain MR
Curr Res Pharmacol Drug Discov; 2022; 3():100102. PubMed ID: 35570856
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
9. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Joharapurkar AA; Patel VJ; Kshirsagar SG; Patel MS; Savsani HH; Jain MR
Drug Dev Res; 2021 Sep; 82(6):852-860. PubMed ID: 33480036
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid modulates iron metabolism imbalance in anemia of inflammation induced by LPS via reversely regulating hepcidin and ferroportin expression.
Han L; Liu Y; Lu M; Wang H; Tang F
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):280-285. PubMed ID: 30446224
[TBL] [Abstract][Full Text] [Related]
11. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in iron status and hepcidin expression in rats.
Kong WN; Niu QM; Ge L; Zhang N; Yan SF; Chen WB; Chang YZ; Zhao SE
Biol Trace Elem Res; 2014 Aug; 160(2):258-67. PubMed ID: 24962641
[TBL] [Abstract][Full Text] [Related]
13. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
14. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice.
Díaz V; Gammella E; Recalcati S; Santambrogio P; Naldi AM; Vogel J; Gassmann M; Cairo G
Hepatology; 2013 Dec; 58(6):2122-32. PubMed ID: 23744538
[TBL] [Abstract][Full Text] [Related]
15. Desidustat: First Approval.
Dhillon S
Drugs; 2022 Jul; 82(11):1207-1212. PubMed ID: 35834123
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
17. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329
[TBL] [Abstract][Full Text] [Related]
18. Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation.
Guo W; Schmidt PJ; Fleming MD; Bhasin S
Endocrinology; 2016 Jul; 157(7):2937-46. PubMed ID: 27074351
[TBL] [Abstract][Full Text] [Related]
19. TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats.
Kato S; Yamamoto K; Uchida S; Takahashi T
Biol Pharm Bull; 2021; 44(11):1653-1661. PubMed ID: 34719642
[TBL] [Abstract][Full Text] [Related]
20. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
